Cargando…

Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines

Neuroblastoma (NB), the most frequent solid extracranial tumor in children, is not always cured by current aggressive therapies that have notable adverse effects; therefore, novel treatments are necessary. Phosphoinositide 3-kinase (PI3K) and fibroblast growth factor receptor inhibitors exhibit syne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lukoseviciute, Monika, Holzhauser, Stefan, Pappa, Eleni, Mandal, Tamoghna, Dalianis, Tina, Kostopoulou, Ourania N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394730/ https://www.ncbi.nlm.nih.gov/pubmed/37477144 http://dx.doi.org/10.3892/or.2023.8603

Ejemplares similares

Combination of PARP and WEE1 inhibitors in vitro: Potential for use in the treatment of SHH medulloblastoma
por: Lukoseviciute, Monika, et al.
Publicado: (2023)

Targeted Therapy of HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy between CDK4/6, PI3K and Sometimes FGFR Inhibitors, but Rarely between PARP and WEE1 Inhibitors
por: Kostopoulou, Ourania N., et al.
Publicado: (2022)

Targeted Therapy with PI3K, PARP, and WEE1 Inhibitors and Radiotherapy in HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy while Effects with APR-246 Are Limited
por: Byskata, Karin, et al.
Publicado: (2022)

Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines
por: Lukoseviciute, Monika, et al.
Publicado: (2021)

Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines
por: Holzhauser, Stefan, et al.
Publicado: (2021)

Targeted Therapy With PI3K and FGFR Inhibitors on Human Papillomavirus Positive and Negative Tonsillar and Base of Tongue Cancer Lines With and Without Corresponding Mutations
por: Holzhauser, Stefan, et al.
Publicado: (2021)

Prognostic Markers and Driver Genes and Options for Targeted Therapy in Human-Papillomavirus-Positive Tonsillar and Base-of-Tongue Squamous Cell Carcinoma
por: Näsman, Anders, et al.
Publicado: (2021)

Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review
por: Nur Husna, Siti Muhamad, et al.
Publicado: (2018)

High Levels of FGF11 Correlate with Poor Survival in Patients with Human Papillomavirus (HPV)-Positive Oropharyngeal Squamous Cell Carcinoma
por: de Flon, Caroline Haglund, et al.
Publicado: (2023)

Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer
por: Seo, Hye-Rim, et al.
Publicado: (2022)

Gauchos and ochos: a Wee1-Cdk tango regulating mitotic entry
por: Enders, Greg H
Publicado: (2010)

Human Cdc14A regulates Wee1 stability by counteracting CDK-mediated phosphorylation
por: Ovejero, Sara, et al.
Publicado: (2012)

WEE1 and PARP-1 play critical roles in myelodysplastic syndrome and acute myeloid leukemia treatment
por: Okabe, Seiichi, et al.
Publicado: (2023)

Impaired DNA double-strand break repair and effective radiosensitization of HPV-negative HNSCC cell lines through combined inhibition of PARP and Wee1
por: Oetting, Agnes, et al.
Publicado: (2023)

Whole-Exome Sequencing of HPV Positive Tonsillar and Base of Tongue Squamous Cell Carcinomas Reveals a Global Mutational Pattern along with Relapse-Specific Somatic Variants
por: Ährlund-Richter, Andreas, et al.
Publicado: (2021)

Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
por: Philip, Charles-André, et al.
Publicado: (2017)

ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms
por: Southgate, Harriet E. D., et al.
Publicado: (2020)

PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
por: Bian, X, et al.
Publicado: (2018)

Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors
por: Fallah, Yassi, et al.
Publicado: (2021)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways
por: Hosford, Sarah R, et al.
Publicado: (2014)

PARP1 gene polymorphisms and neuroblastoma susceptibility in Chinese children
por: Cheng, Jiwen, et al.
Publicado: (2019)

Heterogeneities in Cell Cycle Checkpoint Activation Following Doxorubicin Treatment Reveal Targetable Vulnerabilities in TP53 Mutated Ultra High-Risk Neuroblastoma Cell Lines
por: Ödborn Jönsson, Linnéa, et al.
Publicado: (2021)

Wee1 kinase alters cyclin E/Cdk2 and promotes apoptosis during the early embryonic development of Xenopus laevis
por: Wroble, Brian N, et al.
Publicado: (2007)

The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs
por: Visconti, R, et al.
Publicado: (2015)

High Iodine Induces the Proliferation of Papillary and Anaplastic Thyroid Cancer Cells via AKT/Wee1/CDK1 Axis
por: Lv, Chunpeng, et al.
Publicado: (2021)

Air raids and the 'Wee' Hospital.
por: Logan, C. J. H.
Publicado: (2003)

MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1
por: Creevey, Laura, et al.
Publicado: (2013)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
por: Serra, Violeta, et al.
Publicado: (2022)

Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer
por: Teo, Zhi Ling, et al.
Publicado: (2023)

MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma
por: King, David, et al.
Publicado: (2020)

Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication
por: Sørensen, Claus Storgaard, et al.
Publicado: (2012)

Analysis of Human Papillomavirus (HPV) and Polyomaviruses (HPyVs) in Adenoid Cystic Carcinoma (AdCC) of the Head and Neck Region Reveals Three HPV-Positive Cases with Adenoid Cystic-like Features
por: Zupancic, Mark, et al.
Publicado: (2022)

COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION
por: Johnson, Neil, et al.
Publicado: (2011)

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer
por: Konecny, Gottfried E.
Publicado: (2019)

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
por: Karimi, Leena, et al.
Publicado: (2023)

A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy
por: Westhoff, Mike-Andrew, et al.
Publicado: (2014)

A Wee Lesson in Science Communication
por: King, Emma
Publicado: (2004)

Pedicures, wees alert op ‘coronatenen’
por: van Putten, Margreet
Publicado: (2020)

WEE1 Inhibitor: Clinical Development
por: Kong, Anthony, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7ghh30bk41npio4g635553vo9e